CAS: 100643-27-4; 2,6-Diaminopyrimidin-4-Ol

上下游产品

CAS号7355-55-7 2-氨基-4-羟基吡咯并[2,... | CAS号69205-79-4 2-氨基-4-氧代-4,7-二... | CAS号6312-72-7 5-溴-2,4-二氨基-6-羟基嘧啶 | CAS号33344-18-2 2-amino-6-[(4-m... | CAS号120040-42-8 2-氨基-6-溴吡啶并[2,3... | CAS号22288-77-3 2,5-二氨基-噻唑并[4,5... | CAS号156-83-2 2,4-二氨基-6-氯嘧啶 | CAS号124738-76-7 2-氨基-4,7-二氢-4-氧... | CAS号67194-86-9 5-氯甲基呋喃并[2,3-d]... | CAS号80360-03-8 2-amino-4-oxo-1...

2,4-二氨基-6-氟嘧啶置于sodium Hydroxide体系中,用 甲醇,水 用作溶剂,化学反应生成2,4-二氨基-6-羟基嘧啶
参考文献:Popova; Studentsov,Russian Journal Of General Chemistry,1997,Vol. 67,# 3,P. 435-438
标题:Popova; Studentsov,Russian Journal Of General Chemistry,1997,Vol. 67,# 3,P. 435-438

专利信息

专利号:US-6818633-B2
优先权日:2001-06-29
标题:Antiviral compounds and methods for synthesis and therapy
发明人：BALZARINI JAN M R; DE CLERCQ ERIK D A; HOLY ANTONIN
权利人:ACAD OF SCIENCE CZECH REPUBLIC; REGA STICHTING
摘要:Novel compounds are provided having formula (I)whereR1, R2, R3, R4, Z, X and * are defined herein. Also provided are antiviral methods for use and processes for synthesis of the compounds of formula (I).

专利号:US-2005085492-A1
优先权日:2003-10-20
标 题:Stereoselective process for the synthesis of chiral garft compounds and intermediates
发明人：RAHMAN LEERA
权利人:AGOURON PHARMACEUTICALS MINC
摘要:The present invention describes a stereoselective preparation of derivatives and precursors of molecules having formula 1: n nMethod of preparing the compounds, intermediates and derivatives are described. The methods described herein allow the preparation of diastereomeric forms of compound having formula 1. The compounds of the invention are GARFT inhibitors.

专利号:US-5235053-A
优先权日:1992-06-22
标题 :Process for the synthesis of 4-hydroxy-5-halopyrrold[2,3-d]pyrimidine intermediates
发明人：BARNETT CHARLES J; KOBIERSKI MICHAEL E
权利人:LILLY CO ELI
摘要:4-Hydroxypyrrolo[2,3-d]pyrimidines are regiospecifically halogenated at the C-5 position by silylation in the presence of an inert organic solvent and iodination, bromination or chlorination.

专利号:US-6906185-B1
优先权日:1997-03-20
标 题:Derivatives of 7-deaza -2′-deoxyguanosine-5'-triphosphate, preparation and use thereof
发明人：FULLER CARL W; MCDOUGALL MARK; KUMAR SHIV
权利人:AMERSHAM BIOSCIENCES CORP
摘要:Derivatives of 7-deaza-2'-deoxyguanosine are described. Also described is the use of such compounds in synthesis of nucleic acid polymers and in methods for determining a nucleotide base sequence.

专利号:US-6153615-A
优先权日:1991-12-26
标 题 :Blocking induction of tetrahydrobioterin to block induction of nitric oxide synthesis
发明人：GROSS STEVEN S
权利人:CORNELL RES FOUNDATION INC
摘要:Guanosine triphosphate pathway tetrahydrobiopterin synthesis antagonist and/or pterin salvage pathway tetrahydrobiopterin synthesis antagonists are administered to inhibit nitric oxide synthesis from arginine in vascular cells in a subject in need of such inhibition (e.g., for prophylactic or curative effect for endotoxin- or cytokine-induced hypotension or for restoration of vascular contractile sensitivity to pressor agents in the treatment of such hypotension). The tetrahydrobiopterin synthesis antagonist may be administered with α 1 -adrenergic agonist or with nitric oxide synthase inhibitor. The tetrahydrobiopterin synthesis antagonists are also administered to attenuate inflammation caused by induced nitric oxide production in immune cells. Unwanted counterproductive or side effects can be eliminated or ameliorated by administration additionally of levodopa with or without carbidopa and L-5-hydroxytryptophane.

专利号:US-6274581-B1
优先权日:1991-12-26
标 题 :Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
发明人：GROSS STEVEN S
权利人:CORNELL RES FOUNDATION INC
摘要:Guanosine triphosphate pathway tetrahydrobiopterin synthesis antagonist and/or pterin salvage pathway tetrahydrobiopterin synthesis antagonist are administered to inhibit nitric oxide synthesis from arginine in vascular smooth muscle cells in a subject in need of such inhibition (e.g. for prophylactic or curative effect for cytokine-induced hypotension or for restoration of vascular contractile sensitivity to pressor agents in the treatment of such hypotension).